Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer

Table 4

Univariate analysis and multivariate analysis of overall survival time.

Variable category	Category	HR (95% CI)	value	HR (95% CI)	value
Gender	Female versus male	0.99 (0.64-1.52)	0.955	0.82 (0.48-1.39)	0.468
Age	⩾59 versus <59	1.29 (0.87-1.89)	0.199	1.34 (0.83-2.18)	0.230
ECOG	⩾2 versus 0-1	1.18 (0.67-2.08)	0.557	1.58 (0.85-2.93)	0.146
Tumor_location	Cardia versus body/fundus versus pylorus	0.89 (0.70-1.12)	0.103	0.99 (0.74-1.33)	0.968
Histological_differentiation	Poorly versus moderately and well	1.92 (1.29-2.86)	0.001	1.89 (1.21-2.94)	0.005
No. of metastasis organs	≥2 versus <2	1.39 (0.87-2.20)	0.156	1.15 (0.71-1.87)	0.564
Liver metastasis	Yes versus no	0.84 (0.57-1.25)	0.396	0.88 (0.54-1.41)	0.584
Smoking_history	Smoke versus never smoked	1.40 (0.96-2.06)	0.077	1.38 (0.78-2.43)	0.271
Drinking_history	Drink versus never drinked	0.73 (0.49-1.07)	0.110	0.73 (0.42-1.26)	0.259
Anti-PD-1 therapy line	First line versus second line and third line	0.551 (0.38-0.80)	0.002	0.64 (0.39-1.06)	0.086
Treatment type	Anti-PD-1 plus chemotherapy versus anti-PD-1 monotherapy or antiangiogenesis	0.49 (0.33-0.73)	<0.001	0.73 (0.43-1.24)	0.249
Baseline NLR	<3.23 versus ≥3.23	0.38 (0.26-0.57)	<0.001	0.34 (0.22-0.52)	<0.001

CI: confidence interval; ECOG PS: Eastern Cooperative Oncology Group Performance Status; NLR: neutrophil-to-lymphocyte ratio; HR: hazard ratio.